Cargando…

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little is known about them in thyroid cancer. We investigated the role of PD-L1 in thyroid cancer with respect to BRAF mutation and MAP kin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brauner, Eran, Gunda, Viswanath, Borre, Pierre Vanden, Zurakowski, David, Kim, Yon Seon, Dennett, Kate Virginia, Amin, Salma, Freeman, Gordon James, Parangi, Sareh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941380/ https://www.ncbi.nlm.nih.gov/pubmed/26943572 http://dx.doi.org/10.18632/oncotarget.7839

Ejemplares similares

Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer
por: Borre, Pierre Vanden, et al.
Publicado: (2014)

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
por: Gunda, Viswanath, et al.
Publicado: (2018)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
por: Xu, Zhen, et al.
Publicado: (2023)

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
por: Gunda, V, et al.
Publicado: (2014)

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
por: Nucera, Carmelo, et al.
Publicado: (2011)

Extended anogenital Buschke-Löwenstein tumor in an immunocompetent patient
por: Salim, Salma, et al.
Publicado: (2019)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021)

Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
por: Ng, Thomas S. C., et al.
Publicado: (2022)

An Immunocompetent Microphysiological System to Simultaneously Investigate Effects of Anti-Tumor Natural Killer Cells on Tumor and Cardiac Microtissues
por: Nguyen, Oanh T. P., et al.
Publicado: (2021)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice
por: Neal, Robert E., et al.
Publicado: (2013)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells
por: Pinto, Ana Teresa, et al.
Publicado: (2023)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity
por: Hong, Sungpyo, et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

Inhibition of tumor autophagy: a strategy to improve anti-tumor immunity?
por: Freeman, Andrew J., et al.
Publicado: (2020)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2022)

The multifaceted anti-cancer effects of BRAF-inhibitors
por: Croce, Laura, et al.
Publicado: (2019)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2021)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

Anaplastic thyroid tumor as an embolic source of metastasis
por: González Rodríguez, Paloma, et al.
Publicado: (2022)

Supratentorial tumor resembling anaplastic ependymoma in an adolescent
por: Zaytseva, Margarita, et al.
Publicado: (2023)

A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma
por: Parascandolo, Alessia, et al.
Publicado: (2017)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
por: Pavon, Lorena Favaro, et al.
Publicado: (2019)

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
por: Annaberdyev, Shohrat, et al.
Publicado: (2009)

Radiosurgery for Epidermoid Tumors: Dramatic Pain Relief from Trigeminal Neuralgia
por: Kida, Yoshihisa, et al.
Publicado: (2019)

“Freedom and Dignity Are Worth More than Life”: The Dramatic Suicide of an Anti-Vax Man
por: Sablone, Sara, et al.
Publicado: (2022)

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
por: Bueno, Fernanda, et al.
Publicado: (2021)

A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis
por: Li, Jisong, et al.
Publicado: (2018)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

Oncogenic BRAF Alterations and Their Role in Brain Tumors
por: Behling, Felix, et al.
Publicado: (2019)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qo6vrvlkkanbl8lhcflmnfiqu6